The Ministry of Chemicals and Fertilisers in a written reply in the Rajya Sabha, addressed India's strategic transition toward self-reliance in Active Pharmaceutical Ingredients (APIs), specifically focusing on reducing import dependencies on China.
While India remains a global leader in generic medicine exports, the domestic pharmaceutical industry has historically relied on China for approximately 70% of its total API requirements, with imports of specific life-saving antibiotics and vitamins reaching a 100% dependency level. To mitigate these vulnerabilities, the government is facilitating a structural shift through the Production Linked Incentive (PLI) Schemes and the Bulk Drug Parks Scheme.
These initiatives are designed to foster domestic manufacturing of 53 identified critical APIs and Key Starting Materials (KSMs), acting as a driver for enhancing the resilience of the national healthcare supply chain and ensuring the long-term sustainability of the "Pharmacy of the World".
Key Measures for API Self-Reliance
Incentivising Domestic Production: Implementing the PLI Scheme for Bulk Drugs with a total financial outlay intended to support the local manufacturing of critical KSMs and APIs.
Bulk Drug Parks Scheme: Providing financial assistance for the establishment of three "Bulk Drug Parks" to offer common world-class infrastructure, thereby reducing the cost of production for domestic manufacturers.
Diversification of Import Sources: Encouraging the industry to explore alternative geographies for sourcing raw materials to bypass the risks of over-concentration in a single country.
Focus on 53 Critical APIs: Prioritising the domestic manufacturing of specific ingredients where import dependency is most acute, including fermented-based APIs like Penicillin and Streptomycin.
Infrastructure Support: Strengthening the mechanical linkages between R&D institutions and industry to accelerate the commercialisation of indigenous API technologies.
What is a "Bulk Drug Park"? A Bulk Drug Park is a dedicated zone that provides common infrastructure facilities specifically for the pharmaceutical manufacturing sector. It operates on the mechanical theory of economies of scale; by providing shared resources such as effluent treatment plants, steam plants, and testing labs, the park serves as a foundation for lowering the capital expenditure (CAPEX) for individual units. Reducing these overheads is a prerequisite for making Indian-made APIs price-competitive against imports. These parks act as a primary driver for localising the production of high-volume, low-margin ingredients that were previously outsourced due to cost considerations.
Policy Relevance: Reducing Strategic Vulnerability
Operationalising "Atmanirbhar Bharat": The PLI and Bulk Drug Park schemes serve as a primary mechanic for the Department of Pharmaceuticals to turn the vision of a self-reliant pharma sector into measurable industrial output.
Internalising Supply Chain Security: Reducing the 70% reliance on China is a functional framework for the Ministry of Health to ensure that global supply chain disruptions do not lead to domestic shortages of essential medicines.
Bypassing Cost Barriers: The provision of common infrastructure is a prerequisite for Indian MSMEs to enter the API manufacturing segment, which has traditionally been capital-intensive.
Link to Global Export Leadership: Strengthening the API base is a foundational step for India to maintain its high-fidelity reputation as a reliable supplier of affordable medicines to over 200 countries.
Relevant Question for Policy Stakeholders: How should the Department of Pharmaceuticals define the success parameters for the PLI scheme to ensure that domestic production actually replaces imports rather than merely supplementing them?
Follow the Full Releases Here:
